Table 1 Cases of COVID-19 in French adults with Prader-Willi syndrome between March 2020 and January 2021
Clinical characteristics (n = 38) | ||
Age (years) | 34.1 ± 11.9 [18–60] | |
Gender (%) | Female: 22 (58); Male: 16 (42) | |
Genetic subtype (%) | Deletion: 20 (53); UPD: 16 (42); ICD: 1 (3); unknown:1 | |
Body Mass Index (kg/m2) | 40.6 ± 12.7 [21.5–72.5] | |
Obesity (BMI ≥ 30 kg/m2) (%) | 31 (82) | |
Severe obesity (BMI ≥ 35 kg/m2) (%) | 21 (55) | |
Massive obesity (BMI ≥ 40 kg/m2) (%) | 16 (42) | |
Type 2 diabetes (%) | 12 (32) | |
Type 1 diabetes (%) | 2 (5) | |
Hypertension (%) | 14 (37) | |
Treated apnea syndrome with nocturnal CPAP (%) | 13 (34) | |
Respiratory and/or cardiac failure (%) | 6 (16) | |
Past venous thrombotic events (%) | 5 (13) | |
Living situation at the time of COVID-19 (%) | ||
Residential group home | 19 (50) | |
Living home with family | 8 (21) | |
Hospital | 10 (including 9 from cluster in Hendaye Hospital) | |
Treatments at the time of COVID-19 (%) | ||
Hormones | GH: 4 (11); Thyroxine: 16 (42); SHT: 14 (37); HC: 1 (3) | |
Antidiabetic treatment | 14 (37) | |
Antihypertensive treatment | 14 (37) | |
Lipid lowering therapy | 4 (11) | |
Vitamin D | 23 (61) | |
Topiramate | 9 (24) | |
Antidepressants | 12 (32) | |
Antipsychotics | 21 (55) | |
Anxiolytics | 9 (24) | |
COVID-19 diagnosis (%) | ||
Positive SARS-CoV-2 RT-PCR test | 29 (76) | |
Positive IgG against SARS-CoV-2 after infection | 9 (24) | |
Plaints or clinical signs (%) | 24 (63) | |
Asthenia | 10 (26) | |
Fever | 15 (39) | |
Cough | 7 (18) | |
Shortness of breath | 6 (16) | |
Headache | 4 (11) | |
Diarrhea | 3 (8) | |
Anosmia | 1 (3) | |
No clinical sign or plaints | 14 (37) | |
Evolution of symptomatic patients (%) | ||
Admitted to hospital | 12 (including 9 from cluster in Hendaye Hospital) | |
Admitted to ICU | 0 | |
Death | 0 | |
Complete recovery | 24 (100) | |
Time to complete recovery (days) | 6.1 ± 4.4 [1–21] | |